Beth Israel Deaconess Medical Center, Inc.

Triad National Security, LLC

Janssen Vaccines & Prevention B.v.

Children's Medical Center Corporation

US Government As Represented by the Secretary of the Army

Washington University

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

Janssen Pharmaceuticals, Inc.

University of Pennsylvania

Los Alamos National Security, LLC

Oxford University Innovation Ltd

Crucell Holland B.v.

Beth Israel Deaconess

Dan H Barouch

Joseph P Nkolola

Bette T Korber

Peter Abbink

Maria Grazia Pau

Stephen C Harrison

William M Fischer

Bing Chen

Michael Scott Seaman

Johanna Schuitemaker

Frank Tomaka

Nelson L Michael

Danielle Van Manen

Jennifer Anne Hendriks

Randal Robert Ketchem

Jerald C Sadoff

Drew Weissman

Johannes Petrus Maria Langedijk

Tomas Hanke

Rutilio Clark

Bruce A Kerwin

Bette T M Korber

David Adrianus Theodorus Maria Zuijdgeest

Lucy Rutten

Frank Wegmann

Jerome H Kim

Alison J Gillespie

James Theiler

Christine C Siska

Herbert Virgin, Iv

Julee A Floyd

An Vandebosch

Jintanat Ananworanich

Merlin Robb

Mathieu Claude Michel Le Gars

Mark Johannes Gerardus Bakkers

Christine Bricault

Menzo J E Havenga

Mark Justin Iampietro

Jeremy M Shaver

Rinke Bos

David Huabin Wang

Menzo Jans Emco Havenga

Herbert W Virgin

Karina Yusim

Macaya Julie Douoguih

Kayvon Modjarrad

Larissa Thackray

Guoyan Zhao

Rajeshwer Singh Sankhala

Gaston Rafael Picchio

Rafael Larocca

Joseph P Nkoloa

Scott Handley

Rachel Presti

Richard S Rogers

Vincent Dussupt

Gina Donofrio

Richard G Jarman, Iii

Shelly Krebs

Gordon Joyce

Kathryn Elaine Stephenson

Joseph P Nikolola

Joseph Nkolola

Featured are PGDM1400 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating or curing subjects infected with HIV and/or preventing HIV infections in subjects at risk of HIV transmission using the PGDM1400 variant antibodies or fragments thereof.

Antibody therapies for human immunodeficiency virus (HIV)

Immunogenic compositions and methods of their use in eliciting immune responses to coronaviruses, such as SARS-CoV-2 are provided.

Conserved region T cell vaccines for coronavirus and methods of use

Featured are recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are simian (rhesus) adenoviruses having a low seroprevalence and high immunogenicity (when expressing, e.g., an antigenic polypeptide) relative to other adenoviruses and vectors thereof. Also featured are methods for producing the adenoviruses and methods of treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).

Recombinant adenoviruses and uses thereof

The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.

Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination

Featured are PGT121 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating subjects infected with HIV and/or blocking HIV infections in subjects at risk of HIV transmission using the PGT121 variant antibodies or fragments thereof.

The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response). The present invention relates to isolated nucleic and/or recombinant nucleic acid encoding a coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the coronavirus S proteins, as well as to the use of the nucleic acids and/or proteins thereof in vaccines.

Compositions and methods for preventing and treating coronavirus infection&#x2014;SARS-CoV-2 vaccines

The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.

Antiviral vaccines with improved cellular immunogenicity

Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.

Biochemically stabilized HIV-1 Env trimer vaccine

The invention features immunogenic compositions and vaccines containing an optimized human immunodeficiency virus (HIV) envelope (Env) polypeptide (e.g., a stabilized trimer of optimized HIV Env polypeptides) or a polynucleotide encoding an optimized HIV Env polypeptide and uses thereof. The invention also features methods of treating and/or preventing a HIV infection by administering an immunogenic composition or vaccine of the invention to a subject (e.g., a human).

Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same

Compositions, vaccines and methods for inducing an immunity, including a protective immunity, against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more adenovirus 26 vectors using for priming immunization and an isolated HIV antigenic polypeptide in combination with one or more MVA vectors for boosting immunization induced strong protective immunity against infections by one or multiple clades of HIV.

Compositions and methods for inducing protective immunity against human immunodeficiency virus infection

Described are N332 glycan-dependent antibodies for treating human immunodeficiency virus (HIV) in a subject that is infected with HIV and that is receiving antiretroviral therapy (ART).

Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies in subjects with low viral loads

The invention features stabilized human immunodeficiency virus (HIV) envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.

Stabilized human immunodeficiency virus (HIV) envelope (ENV) trimer vaccines and methods of using same

Growing community of inventors

Newton, MA, United States of America

Dan H Barouch